Advancing regulatory science for medical countermeasure development :
نام عام مواد
[Book]
ساير اطلاعات عنواني
workshop summary /
نام نخستين پديدآور
Theresa Wizemann, Bruce M. Altevogt, and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation ; Forum on Medical and Public Health Preparedness for Catastropic Events, Board on Health Sciences Policy, Institute of Medicine of the National Academies
مشخصات ظاهری
نام خاص و کميت اثر
xviii, 132 pages :
ساير جزييات
illustrations (some color) ;
ابعاد
23 cm
یادداشتهای مربوط به کتابنامه ، واژه نامه و نمایه های داخل اثر
متن يادداشت
Includes bibliographical references (pages 81-82)
یادداشتهای مربوط به خلاصه یا چکیده
متن يادداشت
Whether or not the United States has safe and effective medical countermeasures--such as vaccines, drugs, and diagnostic tools--available for use during a disaster can mean the difference between life and death for many Americans. The Food and Drug Administration (FDA) and the scientific community at large could benefit from improved scientific tools and analytic techniques to undertake the complex scientific evaluation and decision making needed to make essential medical countermeasures available. At the request of FDA, the Institute of Medicine (IOM) held a workshop to examine methods to improve the development, evaluation, approval, and regulation of medical countermeasures. During public health emergencies such as influenza or chemical, biological, radiological/nuclear (CBRN) attacks, safe and effective vaccines, treatments, and other medical countermeasures are essential to protecting national security and the well being of the public. Advancing regulatory science for medical countermeasure development examines current medical countermeasures, and investigates the future of research and development in this area. Convened on March 29-30, 2011, this workshop identified regulatory science tools and methods that are available or under development, as well as major gaps in currently available regulatory science tools. Advancing regulatory science for medical countermeasure development is a valuable resource for federal agencies including the Food and Drug Administration (FDA), the Department of Health and Human Services (HHS), the Department of Defense (DoD), as well as health professionals, and public and private health organizations"--Publisher's description
نام تنالگان به منزله موضوع
موضوع مستند نشده
United States.
موضوع (اسم عام یاعبارت اسمی عام)
موضوع مستند نشده
Chemical agents (Munitions), Congresses
موضوع مستند نشده
Disaster medicine-- United States-- Evaluation, Congresses
موضوع مستند نشده
Emergency management-- United States-- Evaluation, Congresses
موضوع مستند نشده
Weapons of mass destruction-- Health aspects, Congresses
رده بندی کنگره
شماره رده
RA645
.
5
نشانه اثر
.
A287
2011
نام شخص - (مسئولیت معنوی برابر )
مستند نام اشخاص تاييد نشده
Altevogt, Bruce M
مستند نام اشخاص تاييد نشده
Claiborne, Anne B
مستند نام اشخاص تاييد نشده
Wizemann, Theresa M
نام تنالگان _ (مسئولیت معنوی برابر)
مستند نام تنالگان تاييد نشده
Institute of Medicine (U.S.)., Forum on Drug Discovery, Development, and Translation
مستند نام تنالگان تاييد نشده
Institute of Medicine (U.S.)., Forum on Medical and Public Health Preparedness for Catastrophic Events